Your browser doesn't support javascript.
loading
Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 2019-2023, 2019.
Artigo em Chinês | WPRIM | ID: wpr-781501
ABSTRACT
Abstract  Tumor cells avoid immune surveillance by overexpressing ligands of checkpoint receptors on tumor cells or adjacent cells, resulting in inability or exhaustion of T cells. Numerous studies have shown that lymphoma cells highly expressed programmed cell death ligand-1 (PD-L1), suggesting that PD-1 may become an important target for lymphoma treatment. By targeting the PD-1 protein, the cellular activity of T cells will be significantly enhanced, and the tumor growth will be inhibited. Recently, antibodies against PD-1 have shown high efficacy and safety in the clinical studies of lymphoma, which are expected to become the targeted therapeutic drugs for lymphoma. In order to deeply understand the application of PD-1 antibody in treatment of lymphoma, this review briefly summaries the present state of lymphoma studies, the action mechanism and preparation method of PD-1 antibody in clinical treatment of lymphoma.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Apoptose / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Linfoma / Anticorpos Monoclonais Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Apoptose / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Linfoma / Anticorpos Monoclonais Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2019 Tipo de documento: Artigo